Slide 1: Lacutamab in patients with relapsed and refractory Sezary Syndrome: long term follow-up from TELLOMAK
Lacutamab in patients with relapsed and refractory Sezary Syndrome: long term follow-up from the TELLOMAK phase 2 trial Pr Martine BAGOT
Slide 2: Potential sources of conflict of interest
Potential sources of conflict of interest: ▪ Advisory boards: Innate Pharma, Kyowa Kirin, Helsinn/Recordati 2
Slide 3: Lacutamab in patients with relapsed and refractory Sezary Syndrome: long term follow-up (abstract)
#166 LACUTAMAB IN PATIENTS WITH RELAPSED AND REFRACTORY SEZARY SYNDROME: LONG TERM FOLLOW-UP FROM THE TELLOMAK PHASE 2 TRIAL Martine Bagot1, Youn H Kim2, Caroline Ram-Wolff1, Larisa J. Geskin3, Pablo L. Ortiz-Romero4, Ellen Kim5, Neha Mehta-Shah6, Olivier Dereure7, Saskia Oro8, Marie Beylot-Barry9,
Slide 4: Introduction
Introduction • Sézary syndrome (SS): rare and aggressive cutaneous T-cell lymphoma (CTCL) with poor prognosis (10-20% 5-year survival), characterized Mechanism of Action of lacutamab by erythroderma, significant blood involvement, first-in-class humanized anti-KIR3DL2 antibody lymphadenopathy • KIR3
Slide 5: TELLOMAK Phase 2 Study design (NCT03902184)
TELLOMAK Phase 2 Study design (NCT03902184) evaluating lacutamab in patients with R/R MF or SS after at least 2 prior systemic therapies including mogamulizumab. We report here long-term follow-up SS results Sézary Syndrome (N=63) Mycosis Fungoides (N=107) ≥ 2 prior systemic therapies ≥ 2 prior syst
Slide 6: Patient baseline characteristics
Patient baseline characteristics Patient Characteristics at baseline Cohort SS, N=63 Age in years, median (range) 69 (42-86) - Male, N (%) 37 (58.7) - Female, N (%) 26 (41.3) Stage of the disease at baseline, N (%) - Stage IVA1 41 (65.1) - Stage IVA2 22 (34.9) B2 blood involvement at baseline, N (%)
Slide 7: Long term efficacy results in SS patients
Long term efficacy results in SS patients Global Response Response Response Response in Skin in Blood in LN N=63 N=63 N=63 N=52* Best Response, N (%) CR 6 (9.5) 9 (14.3) 21 (33.3) 9 (17.3) PR 21 (33.3) 24 (38.1) 11 (17.5) 6 (11.5) SD 28 (44.4) 27 (42.9) 26 (41.3) 27 (51.9) PD 8 (12.7) 3 (4.8) 5 (7.9
Slide 8: Best Global Response
Best Global Response Best Global Response • ORR = 42.9% (31.4-55.1) • 27 patients achieved Global Response, including 6 CR and 21 PR • All patients in CR are still in CR • Median time to Global Response: 2.8 months (range: 1-10) 8 DCO 17 Oct 2024
Slide 9: Duration of Response
Duration of Response Duration of response (DoR) DoR, in months, median (95% CI) 25.6 (11.0 - NE) Patients still in response, % (95%CI) • at 12 months 70.5 (47.7-84.8) • at 24 months 54.0 (30.6-72.6) Long lasting response (>24 months) in more than half of the responders 9 DCO 17 Oct 2024
Slide 10: Progression-free Survival in SS patients
Progression-free Survival in SS patients Progression Free Survival (PFS) PFS, in months, KM median (95% CI) 8.3 (5.1-18.7) Alive without progression, % (95% CI) • at 12 months 45.1 (31.6-57.7) • at 24 months 28.9 (16.2-42.9) 10 DCO 17 Oct 2024
Slide 11: Patient reported outcome over Time in SS patients
Patient reported outcome over Time in SS patients Itch intensity score over time The presence and severity of pruritus was assessed using a 10 point visual analogue scale (VAS) ranging from 0 (no itch) to 10 (worst imaginable itch) • At baseline, median VAS 6.0, 25% of patients had VAS>8 (severe sco
Slide 12: Safety profile
Safety profile Nb and (%) of pts with at least one Total N= 63 Treatment-emergent adverse events (TEAEs) 61 (96.8) Related TEAEs 36 (57.1) Fatigue 12 (19.0) Most frequent (>5%) related TEAEs Asthenia 6 (9.5) Diarrhea 5 (7.9) Arthralgia 4 (6.3) Serious TEAEs 21 (33.3) Serious related TEAEs 6 (9.5) Re
Slide 13: Patient Case #1 and Patient Case #2
Patient Case #1, ongoing Patient Case #2, ongoing • 58-year-old female • 51-year-old female • 10 previous lines of therapy • 6 previous systemic lines of therapy • Stage IVA2 (N3) at baseline • Stage IVA2 (N3) at baseline • Response ongoing sustained at W189: • Response ongoing sustained at W93: — S
Slide 14: Conclusion
Conclusion • TELLOMAK is a Phase 2 study evaluating lacutamab monotherapy in Cutaneous T-cell lymphoma. • Cohort 1 enrolled relapsed and/or refractory SS patients with ≥ 2 prior systemic therapies including mogamulizumab, a high unmet medical need population with no approved therapy. • Lacutamab dem
Slide 15: Acknowledgment
Acknowledgment • USA (17) • Germany (8) AKILOV Oleg, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania KAUFMANN Roland, Universitätsklinikum Frankfurt, Frankfurt DeSIMONE Jennifer, Inova Health Care Services, Fairfax, Virginia MAGNOLO Nina, Universitaetsklinikum Muenster, Muenste
Slide 16: TELLOMAK - With Thanks
TELLOMAK - NCT03902184 With Thanks 53 active sites • USA (17) • France (10) • Germany (8) • Spain (6) • Italy (4) • Belgium (3) • Poland (3) • Austria (2) Study sponsored by Innate Pharma Thank you to all the patients and their families, our investigators, experts, and site staff 16
Slide 17: 17
17